Dynamic contrast-enhanced magnetic resonance imaging-derived kep as a potential biomarker of matrix metalloproteinase 9 expression in patients with glioblastoma multiforme: A pilot study

Journal of Computer Assisted Tomography

Volumn 36, Issue 1, 2012, Pages 125-130

  Awasthi, Rishi ^a   Pandey, Chandra M ^a   Sahoo, Prativa ^b   Behari, Sanjay ^a   Kumar, Vijendra ^a   Kumar, Shaleen ^a   Misra, Shagun ^a   Husain, Nuzhat ^c   Soni, Priyanka ^c   Rathore, Ram K S ^b   Gupta, Rakesh Kumar ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY KANPUR   (India)

^c UNIVERSITY OF LUCKNOW   (India)

Author keywords

Dynamic contrast enhanced MRI; Glioblastoma multiforme; MMP 9 expression

Indexed keywords

BIOMARKERS; CORRELATION METHODS; ENZYME INHIBITION; MAGNETISM; RESONANCE; TISSUE;

DYNAMIC CONTRAST ENHANCED MRI; DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING; GLIOBLASTOMA MULTIFORME; KAPLAN-MEIER; LOW-HIGH; MATRIX METALLOPROTEINASE 9 EXPRESSION; MATRIX METALLOPROTEINASE-9; PEARSON CORRELATION; PILOT STUDIES; TISSUE MATRIX;

DYNAMIC CONTRAST ENHANCED MRI;

GELATINASE B;

ADULT; ARTICLE; BRAIN PERFUSION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84863053936     PISSN: 03638715     EISSN: 15323145     Source Type: Journal    
DOI: 10.1097/RCT.0b013e31823f6c59     Document Type: Article

References (18)

1. Persidsky Y, Ramirez SH, Haorah J, et al. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol. 2006;1:223-236. (Pubitemid 44244128)
2. Parks WC, Wilson CL, López-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol. 2004;4:617-629. (Pubitemid 39025047)
3. Bart J, Groen HJ, Hendrikse NH, et al. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev. 2000;26:449-462. (Pubitemid 32094862)
4. Biernat W, Tohma Y, Yonekawa Y, et al. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol (Berl). 1997;94:303-309. (Pubitemid 27450108)
5. Lo EH, Wang X, Cuzner ML. Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J Neurosci Res. 2002;69:1-9. (Pubitemid 34734159)
6. Kerkelä E, Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol. 2003;12:109-125. (Pubitemid 36934696)
7. Polette M, Nawrocki-Raby B, Gilles C, et al. Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol. 2004;49: 179-186. (Pubitemid 38251350)
8. Choe G, Park JK, Jouben-Steele L, et al. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res. 2002;8:2894-2901. (Pubitemid 35025737)
9. Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low grade) astrocytoma. J Neurosurg. 1993;79: 533-536. (Pubitemid 23289810)
10. Singh A, Haris M, Rathore D, et al. Quantification of physiological and hemodynamic indices using T(1) dynamic contrast-enhanced MRI in intracranial mass lesions. J Magn Reson Imaging. 2007;26: 871-880. (Pubitemid 47548145)
11. Paul R, Lorenzl S, Koedel U, et al. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann Neurol. 1998;44:592-600. (Pubitemid 28477846)
12. Haris M, Husain N, Singh A, et al. Dynamic contrast-enhanced (DCE) derived transfer coefficient (ktrans) is a surrogate marker of matrix metalloproteinase 9 (MMP-9) expression in brain tuberculomas. J Magn Reson Imaging. 2008;28:588-597.
13. Candelario-Jalil E, Taheri S, Yang Y, et al. Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther. 2007;323:488-498. (Pubitemid 350005134)
14. Sood RR, Taheri S, Candelario-Jalil E, et al. Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J Cereb Blood Flow Metab. 2007;1-8.
15. Roberts HC, Roberts TP, Brasch RC, et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol. 2000;21:891-899. (Pubitemid 30262836)
16. Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol. 2004;25:746-755. (Pubitemid 38657655)
17. Zhao Y, Xiao A, diPierro CG, et al. An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase-9. Am J Pathol. 2010;176:3032-3049
18. Hormigo A, Gu B, Karimi S, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res. 2006;12:5698-5704. (Pubitemid 44629598)